2017 was a strong year for China equities
2017 was a strong year for Chinese equities with the economy performing better than expected and many stocks rising from low valuations. Through the year, many companies were rerated and some Chinese companies delivered strong earnings growth.
Valuations remain reasonable
While valuations have risen, we are still optimistic on prospects for 2018 and believe valuations currently look reasonable compared to fundamentals.
Different from previous years, fundamental factors have been behind the recent rise in the market and we see little reason for that to change in 2018.
Fundamental factors are driving performance
Healthcare, IT and consumer sectors have their own fundamental growth drivers that are propelling growth as China undergoes profound economic and social changes and these drivers are largely unaffected by slight changes in China’s macroeconomic statistics.
Take healthcare as an example, there is an undersupply of health services in China but demand is growing due to fundamental changes in China’s economy and society, such as ageing population, increasing incomes, and changing lifestyle aspirations.
Spending on healthcare remains low by international standards but this is changing as these fundamental factors play out. In fact, we have seen strong growth in industry revenues in recent years and we expect this to continue as health spending per capita increases and potentially exceeds levels in more developed economies.
New economy sectors are emerging; Chinese firms becoming more competitive
China’s economy is seeing profound changes with many new sectors emerging from economic rebalancing that have great potential for growth over the long-term.
We have witnessed these changes first-hand from our numerous visits to companies in China. Chinese companies are attracting the talent, building the innovative capacity, and developing the products to compete globally.
Take our recent visit to a China-based pharmaceutical developer for example. At that company, world-class scientists previously at global rivals now lead their drug and product development. This shows the company has the potential to recruit the best talent that will soon deliver a range of advanced, globally competitive products.
Improving corporate governance in China will also promote investors’ understanding of the Chinese companies. We believe that the quality of companies currently in the Chinese equity markets is much higher than before, and that raises the prospect of sustained performance in the markets over the longer term.
Onshore markets more accessible than ever; overseas investors increasingly active
As China’s equity opportunity set changes, China’s equity markets are becoming more accessible than ever. The launch of the Shenzhen-Hong Kong Stock Connect in late 2016, following the Shanghai-Hong Kong Stock Connect in 2014, has opened up a wide range of opportunities for overseas investors.
Overseas investors are allocating more capital to China’s equity markets, with aggregate figures showing foreign investors’ total holdings reached RMB 1.021 trillion at the end of September 2017, a 50% increase from the RMB 656.2 billion recorded at the same point in 2016, according to data compiled by People’s Bank of China.
Overseas investors will likely become more active in the market when 222 A-share stocks enter the MSCI benchmarks in June 2018. The 222 names to be included are all blue-chip companies and may get a boost in 2018 as overseas investors step up their capital allocations.
Optimistic on 2018, many opportunities in the market
So we are positive on the outlook for Chinese equities markets in 2018. We maintain that the profound changes playing out in China’s economy are creating many attractive opportunities, particularly in ‘new economy’ sectors like healthcare, IT and insurance. Investors can be confident about the future because a changing China is offering significant opportunities for growth.
6 members of our emerging market equities team was on the ground in India recently to understand the slowdown in India. More
THIS WEBSITE IS NOT INTENDED FOR AND SHOULD NOT BE ACCESSED BY PERSONS LOCATED OR RESIDENT IN ANY JURISDICTION WHERE (BY REASON OF THAT PERSON'S NATIONALITY, DOMICILE, RESIDENCE OR OTHERWISE) THE PUBLICATION OR AVAILABILITY OF THIS WEBSITE IS PROHIBITED OR CONTRARY TO LOCAL LAW OR REGULATION OR WOULD SUBJECT ANY UBS ENTITY TO ANY REGISTRATION OR LICENSING REQUIREMENTS IN SUCH JURISDICTIONS. IT IS YOUR RESPONSIBILITY TO BE AWARE OF, TO OBTAIN ALL RELEVANT REGULATORY APPROVALS, LICENCES, VERIFICATIONS AND/OR REGISTRATIONS UNDER, AND TO OBSERVE ALL APPLICABLE LAWS AND REGULATIONS OF ANY RELEVANT JURISDICTION IN CONNECTION WITH YOUR ENTRANCE TO THIS WEBSITE. EACH INVESTMENT PRODUCT AND SERVICE REFERRED TO ON THIS WEBSITE IS INTENDED TO BE MADE AVAILABLE ONLY TO RESIDENTS IN SINGAPORE.
UBS RESERVES THE RIGHT TO CHANGE, MODIFY, ADD OR REMOVE CONTENT ON THE WEBSITE AS WELL AS THESE TERMS AT ANY TIME FOR ANY REASON WITHOUT NOTICE. SUCH CHANGES SHALL BE EFFECTIVE IMMEDIATELY UPON POSTING. YOU ACKNOWLEDGE THAT BY ACCESSING OUR WEBSITE AFTER WE HAVE POSTED CHANGES TO THESE TERMS, YOU ARE AGREEING TO THESE TERMS AS MODIFIED.